JNJ vs MRNA
By Alex · Tickerpine
Johnson & Johnson vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | MRNA |
|---|---|---|
| Price | $254.66 | $67.27 |
| Market cap | $613.02B | $26.69B |
| P/E ratio | 29.5 | — |
| ROE | 26.42% | -36.56% |
| Profit margin | 21.83% | -143.55% |
| Revenue growth | 9.90% | 260.20% |
| Dividend yield | 2.10% | — |
| Beta | 0.26 | 1.03 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs MRNA in plain English
- JNJ is the bigger company — about 23.0× the market cap of MRNA.
- JNJ earns a higher return on equity (26% vs -37%).
- MRNA is growing revenue faster (260% vs 10%).
- JNJ pays a dividend (2.10%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.